# Pizarra — PT-pseudo_259484ae733f (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_259484ae733f
Task: 1

Encounter: Urology - outpatient on 04 Jan 2025.
Referrer: Dr. T. Hendriks (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 65-year-old male
  - PSA: 5.3 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.092 ng/mL²
  - PSA velocity: 1.37 ng/mL/yr
  - Prior PSA: 4.3 ng/mL
  - Prostate volume: 57.56 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.79137033 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 5.3 ng/mL. PI-RADS 4. PSAD 0.09. Prostate volume 58 mL. csPCa 0.79.

Vitals: weight 115 kg, height 190 cm, BMI 31.9, BP 132/83 mmHg, HR 81 bpm. Smoking: Ex-smoker (30 pack-yr, quit 2021).

Chief complaint: Current visit addresses a PSA escalation to 5.3 ng/mL against the backdrop of a prior biopsy yielding ISUP grade group 2.

History: First assessed for an elevated PSA reading in late 2023, this 65-year-old man has undergone regular serial testing since. A 30 pack-year smoking history is noted, with cessation achieved in 2021. He operates as an independent delivery driver and requested appointment times that accommodate his schedule. Married status applies, yet he resides by himself; his adult daughter acts as the main emergency contact. Lower urinary tract complaints are moderate, quantified at an IPSS of 13, and currently require no pharmacological intervention. Daily walks lasting twenty minutes form part of his routine, alongside a weekly alcohol consumption capped at two units. A 2018 knee arthroscopy stands as his only significant past surgical event, while recent memory and hearing evaluations returned normal results.

Physical examination: DRE — texture: smooth and firm; dimensions: symmetrically enlarged; palpation: negative for nodules or asymmetry. Systemic assessment shows stable vitals with no evidence of acute or chronic systemic disease.

Patient info: delivery driver; Married; Lives alone; adult daughter is primary contact.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 2 units / week; exercise Walking 20 min/day; IPSS score: 13/35 (moderate LUTS).

Recent other appointments: Memory clinic — baseline screening; Audiology — hearing test; Pulmonary function test — known COPD follow-up.
Admin: Patient self-employed; flexible appointment slots requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.57 +/- 0.10   (95% CI 0.38-0.76)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.10  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 0.99 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'discuss': p +/- dp straddles 0.5. The classifier genuinely CANNOT tell the two answers apart here. Its number is a starting point only. Measured accuracy in this tier on the labelled cohort: 0.488 over 43 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the current mpMRI lesion size/zone compare against an earlier study?
  - psa_trend (get_psa_trend) -> What is the serial PSA trend beyond the headline value?
  - previous_notes (get_previous_notes) -> What was the prior grade, surveillance pathway, and management agreement?

This case hinges on the retrieved documents to determine if the prior positive biopsy status, combined with current findings (PSA rise, PI-RADS 4), warrants a re-biopsy or deferral, as the visible panel is inconclusive. Agenda capped at 3 documents; dropped laboratory_results.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical model only weighed the structured panel, failing to incorporate the context of the rising PSA velocity (1.37 ng/mL/yr) and the specific prior diagnosis (ISUP grade group 2), which are critical for risk stratification.
The model did not process the prose of the mpMRI report, meaning it missed any potential information regarding lesion stability or change since the prior biopsy.
The model did not explicitly weigh the clinical context of the prior positive biopsy status against the current PI-RADS 4 score in the context of the guideline's specific decision tree.

WHY THE SUGGESTION COULD BE WRONG
The prior probability of 0.57 +/- 0.10 places the decision in the 'discuss' tier, suggesting the model cannot distinguish between biopsy and no biopsy based on the visible data. This is likely because the panel lacks the specific trajectory data (PSA trend) and the specific imaging comparison data (lesion change) required by the protocol.
The high aleatoric uncertainty (H=0.99) indicates the disagreement is in the data, not the model, suggesting the visible data is inherently ambiguous for this decision.
The model failed to account for the guideline's requirement that the decision must be derived from retrieved documents, which it did not attempt to do.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the current mpMRI lesion size/zone compare against an earlier study?
psa_trend - What is the serial PSA trend beyond the headline value?
previous_notes - What was the prior grade, surveillance pathway, and management agreement?
previous_notes - What was the prior grade, surveillance pathway, and management agreement?

GUIDELINE ANCHOR
The guideline states that the decision must come from retrieved documents: "The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed."

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
Amsterdam UMC (VUmc) Radiology | 04 January 2025
FINDINGS: The gland spans a volume of 57.56 mL. T2 sequences highlight an 18 mm focal hypointense focus at the posterior left peripheral zone. Diffusion-weighted imaging shows pronounced restriction, mirrored by low ADC signal. Dynamic contrast studies capture early, focal enhancement against the background parenchyma. Extracapsular extension and seminal vesicle invasion are absent. Pelvic lymph nodes and the bladder appear normal.
IMPRESSION: PI-RADS 4 lesion in the left peripheral zone. PSAD 0.092 ng/mL/mL. csPCa predicted probability 0.79137033.

get_psa_trend
[{"date": "Oct 2023", "val": 3.3}, {"date": "Feb 2024", "val": 3.7}, {"date": "May 2024", "val": 4.2}, {"date": "Sep 2024", "val": 4.7}, {"date": "Jan 2025", "val": 5.3}]

get_previous_notes
{"date": "10 Jan 2024", "author": "Dr. T. Hendriks (GP)", "text": "On 10 January 2024, Dr. T. Hendriks documented a PSA trajectory climbing from 1.7 ng/mL in October 2023 to 2.7 ng/mL by February 2024. In light of a previously positive biopsy and an IPSS score of 13 reflecting moderate lower urinary tract symptoms, a urology clinic referral was arranged for comprehensive assessment."}

NOT RETRIEVED
laboratory_results
Left closed because the moderator's agenda did not explicitly require the full lab panel, and the retrieved documents provided sufficient context for the decision based on the agenda items.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- PSA trend shows a clear upward trajectory: 3.3 (Oct 2023) to 5.3 (Jan 2025).
- MRI shows a PI-RADS 4 lesion (18 mm) in the left peripheral zone.

AGAINST sampling this patient now:
- Prior biopsy result: ISUP grade group 2.
- Previous notes indicate a referral was arranged, but no explicit decision on re-biopsy or surveillance protocol is documented.

WHERE THIS LEANS
The evidence strongly suggests a need for further investigation due to the rising PSA and the presence of a high-risk MRI finding, despite the prior positive biopsy.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=yes, protocol=abstains, evidence=yes.
Consensus: yes — unanimous among those who took a position.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved evidence (rising PSA trend and PI-RADS 4 MRI finding) strongly supports the need for further investigation, leading to a lean towards biopsy, despite the prior positive biopsy status.

The chair decides on the record as it stands.

## [9] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

The decision leans toward biopsy because the retrieved PSA trend showed a clear upward trajectory from 3.3 ng/mL in Oct 2023 to 5.3 ng/mL in Jan 2025, and the mpMRI identified a PI-RADS 4 lesion. Although the prior biopsy yielded an ISUP grade group 2, the rising PSA and high-risk imaging finding necessitate further investigation to establish a definitive grade for management planning. The statistical prior suggested biopsy, and the retrieved evidence confirmed the need for further tissue sampling.

Variables that carried weight: bx=important, age=important, psa=important, vol=noted, psad=important, pirads=important, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
